covac-2
Vaccineexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 10, 2021 (NCT04702178)
Timeline
Indications
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05209009 | Phase 2 | Aug 24, 2022 | Government of Canada, Government of Saskatchewan, SEPPIC, Paris, University of Saskatchewan, Vaccine Formulation Institute (VFI) |
| NCT05226702 | Phase 1/Phase 2 (Phase 2) | Jul 22, 2022 | Government of Canada, Government of Saskatchewan, SEPPIC, Paris, University of Saskatchewan, Vaccine Formulation Institute (VFI) |
| NCT04702178 | Phase 1 | Feb 10, 2021 | Canadian Center for Vaccinology, Government of Canada, Government of Saskatchewan, SEPPIC, Paris, University of Saskatchewan, Vaccine Formulation Institute (VFI) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of Canada | Government | 3 | 0 | 2 | 2021 |
| Government of Saskatchewan | Government | 3 | 0 | 2 | 2021 |
| SEPPIC, Paris | For profit | 3 | 0 | 2 | 2021 |
| University of Saskatchewan | Academic/Hospital | 3 | 3 | 2 | 2021 |
| Vaccine Formulation Institute (VFI) | Academic/Hospital | 3 | 0 | 2 | 2021 |
| Canadian Center for Vaccinology | Academic/Hospital | 1 | 0 | 1 | 2021 |
6 organizations
Page 1 / 1